SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.1% - Here's Why

Key Points

• Shares fell 8.1% on Friday to about $4.27 with volume (~1.7M) down ~78% from its average daily trading, after a prior close of $4.64.
• Analyst opinions are mixed: Maxim raised its price target to $10 and gave a "buy," Weiss Ratings kept a "sell," and the MarketBeat consensus is a Hold with a $10 consensus price target.
• SELLAS is a clinical-stage biotech (market cap ~$804M) developing a WT1-targeting peptide vaccine (galinpepimut‑S/GPS); it reported Q1 EPS of ($0.05), beating estimates by $0.01, while FY estimates remain negative (about -$0.29).

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) shares were down 8.1% on Friday . The stock traded as low as $4.25 and last traded at $4.2650. Approximately 1,706,467 shares traded hands during trading, a decline of 78% from the average daily volume of 7,658,134 shares. The stock had previously closed at $4.64.

Analyst Upgrades and Downgrades

SLS has been the topic of a number of analyst reports. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a "buy" rating in a research note on Thursday, March 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Tuesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $10.00.

SELLAS Life Sciences Group Trading Down 3.5%

The company's fifty day simple moving average is $4.80 and its 200 day simple moving average is $3.39. The firm has a market capitalization of $804.34 million, a P/E ratio of -17.90 and a beta of 2.22.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts predict that SELLAS Life Sciences Group, Inc. will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Axxcess Wealth Management LLC purchased a new position in SELLAS Life Sciences Group during the 3rd quarter valued at about $26,000. Larson Financial Group LLC purchased a new position in shares of SELLAS Life Sciences Group during the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets boosted its position in shares of SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock worth $32,000 after purchasing an additional 9,299 shares in the last quarter. Concurrent Investment Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group in the 4th quarter worth approximately $38,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in shares of SELLAS Life Sciences Group in the 4th quarter worth approximately $38,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.